The Company

Lighthouse Biosciences' NanoLantern™ platform and its proprietary methodology for creating uniquely specific probes has allowed the company to develop three, strong, market approaches: development of small and efficient diagnostic instrumentation, customization of platforms with specific pathogen DNA capture probes for the NanoLantern™ based instrumentation, and select sub-licensing the NanoLantern™ technology.